To conclude, as predictive testing in NSCLC becomes more and more complex and further treatable targets (besides EGFR, ALK, ROS1, MET, RET, BRAF, HER2, PD-L1) will arise in the nearer future [2], pragmatic approaches (reliable, not time and money consuming, multiplexable) are needed. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.